Our laboratory is interested in improving treatment for patients with glioblastoma (GBM) and other cancers. We work on understanding signal transduction pathways involved in the pathogenesis of cancer. Recent work has focused on investigating mechanisms of resistance to targeted treatment in GBM and lung cancer. We are also interested in mechanisms regulating invasion in GBM.
Our goal is to understand and exploit the immunogenic properties of tumor irradiation in integrating it with immunotherapy to improve cancer patient outcome.
Dr. Harbour’s research focuses on the use of genetic and genomic technology, cell culture experiments and genetically modified experimental models to understand mechanisms of tumor progression in major forms of eye cancer, including uveal melanoma, retinoblastoma, intraocular lymphoma and others.
The goal of our research lab is to identify the early steps in the pathogenesis of AMD, and to investigate the novel methods to treat and even to prevent its development.
The goal of the Herz Lab is to identify the underlying biochemical principles of human diseases & disorders in order to design novel therapies to prevent, delay, or cure them.
HIFU Lab's research is focused on High-Intensity Focused Ultrasound (HIFU) , which is a form of image-guided therapy capable of non-invasive tissue ablation and drug delivery.
The Core supports the early, pre-clinical discovery and development of new small molecule therapeutics, and assists in identifying and characterizing novel biological targets and pathways for therapeutic intervention.
We do difficult experiments at the frontier of cell physiology, often with our own methods and always with our own hands. Enter a description of the lab. This information will appear on the lab listing page.
Our lab focuses on investigating the brain circuits implicated in treatment resistant depression with the ultimate goal of developing novel therapies for this devastating disease.
We explore questions on genomes using a systems biology approach: developing and employing integrative approaches at the interface of gene regulation, epigenetics, single-cell genomics, and bioinformatics.
We are multidisciplinary team of clinicians and scientists, focusing on liver cancer risk-predictive molecular biomarkers specific to clinical contexts (ex. geographic region, liver disease etiology, and patient race/ethnicity) individual risk-stratified personalized cancer screening.
In diseases like cancer, signaling pathways can be corrupted by mutations that cause the cells to grow and spread uncontrollably. Our lab is interested in understanding how these defective pathways reprogram cellular metabolism to drive cancer growth.
Jer-Tsong Hsieh Lab research interests focus on key molecular mechanisms leading to urologic cancer progression, development of precision medicine of cancer therapy assisted with non-invasive molecular imaging.
Ming-Chang Hu Lab strives to offer novel insight into the cellular and molecular mechanisms of AKI progression to CKD and cardiovascular diseases (vascular calcification and uremic cardiomyopathy) development in CKD, and set up a solid basis for preclinical and clinical study in the future.
The research of the Huang Laboratory focuses on understanding the function of fibroblast progenitor cells and fibroblasts in regulating the immune system.
Our laboratory is interested in the molecular mechanisms governing cytokine receptor signal transduction in hematopoietic stem and progenitor cells, and understanding how deregulation in these mechanisms results in hematological malignancies and cancer.
The Huber lab is focused on understanding how activity-regulated transcription and translation in neurons controls synapse and circuit plasticity and development.
The Hulleman Laboratory is committed to understanding and rectifying the underlying causes of inherited and idiopathic eye disorders caused by protein misfolding.